A new brachytherapy device for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a special device (Maastro applicator) that delivers radiation directly to rectal tumors from inside the rectum. It is for people with rectal cancer who can have this type of internal radiation therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with rectal cancer and the main tumor is in a location where the new device can reach it.
- Your doctor believes this internal radiation treatment is a good option for you.
- You are healthy enough to have sedation or anesthesia and the procedure.
- You can follow study instructions, have imaging tests, and come to scheduled visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects data from people treated with a special rectal applicator for rectal cancer. The goal is to observe long-term outcomes and improve future treatments.
This trial tests a special type of internal radiation (brachytherapy) for people with low-lying rectal cancer that did not fully go away after standard chemoradiation and chemotherapy. The goal is to shrink the remaining tumor enough to avoid major surgery like removing the rectum or colostomy.
This trial tests a combination of two types of radiation therapy (external beam and high-dose-rate brachytherapy) for elderly or frail patients with rectal cancer who cannot or choose not to have surgery. The goal is to see if this approach is effective and well-tolerated.
This trial tests a special type of contact X-ray (brachytherapy) for early-stage rectal cancer. It may help avoid major surgery by treating the tumor from inside the rectum.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests whether combining chemotherapy with high-dose radiation guided by MRI (a special scan) can better treat low rectal cancer. It may help shrink the tumor and improve local control while targeting the tumor more precisely.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.